NeuroRx’s Covid-19 treatment was already shot down by the FDA once, and it failed the primary endpoint in a Phase IIb/III readout — but that won’t stop CEO Jonathan Javitt from lining up a Hail Mary pass to regulators.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,